Physician profile
Muhammed H Zahra
NPI 1609842319
$6,009.98
in general payments reported to CMS, 2019-2025
26 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $474 · 2021: $1,614 · 2022: $1,001 · 2023: $865 · 2024: $998 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.88 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $731.92 | 2019-2024 | Tyvaso, Orenitram |
| Janssen Pharmaceuticals, INC | $568.80 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $566.67 | 2019-2024 | Opsumit |
| Novartis Pharmaceuticals Corporation | $540.57 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $530.78 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $394.07 | 2019-2024 | Farxiga |
| Azurity Pharmaceuticals, INC. | $333.24 | 2023-2025 | Edarbyclor, Edarbyclor, Edarbi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.03 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $290.11 | 2020-2023 | |
| Novo Nordisk INC | $239.12 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $200.84 | 2019-2024 | |
| Astellas Pharma US INC | $198.00 | 2021 | |
| Amgen INC. | $176.15 | 2020-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.63 | 2019-2025 | Lifevest |
| Scpharmaceuticals INC. | $150.44 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $137.95 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $127.04 | 2019-2023 | |
| Esperion Therapeutics, INC. | $101.65 | 2021-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $93.16 | 2019-2021 | |
| Amarin Pharma, INC. | $34.89 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $30.57 | 2024 | |
| Gilead Sciences, INC. | $29.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.00 | 2019 | |
| Abbott Laboratories | $20.69 | 2020 | |
| Genzyme Corporation | $20.08 | 2020 | |
| Cvrx, INC. | $10.79 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammed Zahra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.